MediGO
Acquisition in 2023
MediGO is a logistics platform focused on the real-time management of time-sensitive medical resources, specifically for organ transportation. The platform utilizes proprietary algorithms and machine learning to provide accurate tracking and estimated times of arrival, enhancing supply chain transparency. By offering features such as real-time monitoring of organ location, temperature, and environmental conditions, MediGO allows medical professionals to make informed logistics decisions. Its centralized communication system enables care teams to unify stakeholders and coordinate resources effectively, ultimately optimizing the transplant supply chain. This approach aims to save time, reduce costs, and improve outcomes in organ transplantation.
MedActionPlan
Acquisition in 2021
MedActionPlan specializes in patient medication management, particularly for transplant patients. The company offers a web-based platform designed to enhance medication safety and adherence. Its technology provides patient-centered tools that simplify post-transplant medication regimens, including up-to-date schedules, reminders, and a monitoring dashboard for tracking patient progress. By facilitating effective communication and management of medication schedules, MedActionPlan aims to improve patient adherence and overall healthcare outcomes, while also helping healthcare professionals reduce costs and enhance patient satisfaction.
Transplant Hero
Acquisition in 2021
Transplant Hero develops mobile applications designed to assist transplant patients in managing their medication regimens. The company's primary offering is a smartphone app that features an alarm system to notify users when it is time to take their medications. In addition to reminders, the app provides interactive logging functionality, allowing patients to track their medication events. This approach not only promotes adherence to immunosuppression medication schedules but also offers positive reinforcement to encourage consistent medication-taking behavior. By focusing on the unique needs of transplant patients, Transplant Hero aims to improve health outcomes and enhance the quality of life for this demographic.
Miromatrix Medical
Series C in 2021
Miromatrix Medical Inc. is a biotechnology company focused on developing fully biological human organs and organ-derived products to address the critical shortage of transplantable organs. Utilizing patented perfusion decellularization and recellularization technologies, the company creates products such as MIROMESH, a non-crosslinked acellular surgical mesh for soft tissue repair, and various MIRODERM wound matrixes designed for advanced wound care management. Miromatrix's product pipeline includes innovative solutions like the Miroliver, a bioengineered liver for treating liver failure, and Mirokidney, a fully implantable kidney for end-stage renal disease. Founded in 2009 and based in Eden Prairie, Minnesota, Miromatrix Medical serves a global customer base, focusing on enhancing patient outcomes through its pioneering advancements in organ engineering and wound care solutions.
BFS Molecular
Acquisition in 2021
BFS Molecular is a global company specializing in molecular diagnostics, focused on enhancing post-transplantation patient care. The company develops advanced molecular diagnostics software and provides post-transplant monitoring tests that utilize Next Generation Sequencing (NGS) technology, specifically leveraging reliable and scalable Illumina platforms. By offering innovative solutions and high-quality results, BFS Molecular aids physicians in the early detection of transplant rejection and disease relapse, thereby improving patient outcomes in transplantation medicine.
TransChart
Acquisition in 2021
TransChart specializes in developing patient management software tailored for the transplant continuum, covering organs such as kidney, heart, lung, liver, pancreas, and small bowel. The company's software is highly configurable and includes core functionalities alongside various add-on modules, allowing it to address a wide range of needs, including regulatory compliance, data analytics, and marketing. By facilitating improved management of patient data and transplant cases, TransChart supports hospitals and transplant centers in enhancing their operational efficiency and effectiveness.
XynManagement
Acquisition in 2019
XynManagement, Inc. is a healthcare analytics provider based in Boerne, Texas, specializing in software solutions for transplant quality tracking and waitlist management. Established in 2014, the company focuses on addressing critical challenges faced by transplant centers by offering tools that simplify the Quality Assessment and Performance Improvement (QAPI) processes. Its flagship product, XynQAPI, enables transplant professionals to evaluate candidate and donor risks, monitor center-level performance in real time, and ultimately enhance patient care. As a subsidiary of CareDx, Inc. since 2019, XynManagement continues to support healthcare institutions with automated solutions that analyze quality and outcomes data effectively.
OTTR Chronic Care Solutions
Acquisition in 2019
OTTR Chronic Care Solutions specializes in organ transplant patient tracking software designed for healthcare providers, including physicians, nurses, and administrators. The company's software enhances the quality of patient care by streamlining workflow management, which reduces operational costs and increases case-load efficiency. By providing real-time access to critical information, OTTR's solutions expedite external reporting and support clinical research, ultimately optimizing patient safety. Currently, OTTR serves over 200 programs across more than 60 transplant centers in the United States and Canada, with additional offerings in the U.K., Saudi Arabia, and Australia. As a leader in this niche, OTTR plays a crucial role in improving the overall transplant process.
Allenex
Acquisition in 2015
Allenex AB is a life science company based in Stockholm, Sweden, focused on developing, manufacturing, marketing, and selling products for the transplantation of blood stem cells and organs globally. The company specializes in genomic Human Leukocyte Antigens (HLA) typing kits used to match donors and recipients before hematopoietic stem cell and organ transplants. Additionally, Allenex offers XM-ONE, a range of products and services tailored for organ transplantation. Its research initiatives include an AB0 column designed for transplants between individuals with different blood groups and an AB0 diagnostic test that assesses blood group antibodies. Allenex distributes its products primarily through sub-distributors to laboratories engaged in transplantation diagnostics. Originally founded in 1998 as LinkMed AB, the company rebranded to Allenex AB in June 2011.
ImmuMetrix
Acquisition in 2014
ImmuMetrix, Inc. is a biotechnology company based in Palo Alto, California, founded in 2010. It specializes in transplant diagnostics and the development of immune profiles, which play a crucial role in the treatment of gene-carried diseases. The company's focus on improving diagnostic and therapeutic approaches positions it at the intersection of biotechnology and healthcare, aiming to enhance patient outcomes through innovative solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.